Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for postoperative depressive states and analgesia in traumatic orthopedic surgery
ChiCTR2500114156Phase 4Completed
- Sponsor
- Jiangxi Provincial People's Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine in major depressive disorder (MDD) and Pain due to traumatic fracture of lower limb (3 arms), sponsored by Jiangxi Provincial People's Hospital. Primary endpoints: Hamilton Depression Scale score and Total postoperative sufentanil consumption. Started Dec 2025; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)Pain due to traumatic fracture of lower limb
Beyond the preview
Go deeper on ChiCTR2500114156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114156.